Oncology

Your Article Summary

See Latest Articles

Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases
Anti-Cancer Drugs, 07/28/09

Fushida S et al. - In a trial to determine the maximum tolerated dose (MTD) and the dose-limiting toxicities as well as to evaluate the feasibility of chemotherapy with combined docetaxel, cisplatin, and S-1 (DCS therapy) in a preoperative setting, and also examine the pathological response, it was reported that preoperative DCS therapy was considered feasible and provided a high pathological response rate in gastric cancer pts with para-aortic lymph node metastases.

• 15 pts received intravenous docetaxel and cisplatin (30, 35 or 40 mg/m2, each dose escalation was reciprocal) on days 1 and 15 and oral S-1 (40 mg/m2 twice daily) on days 1-14 every 4 wks.
• After 1 cycle of chemotherapy, toxicities were evaluated and after 2 cycles of chemotherapy, pts who were judged to be candidates for curative resection underwent gastrectomy with D2 lymphadenectomy plus para-aortic lymph node dissection.

• MTD was presumed to be at dose level 3 (docetaxel 40 mg/m2 and cisplatin 35 mg/m2).
• Dose-limiting toxicities were grade 4 neutropenia in 1 pt, grade 3 febrile neutropenia in 2 pts, and grade 3 diarrhoea in 2 pts.
• 13 of 15 pts received complete resection and there was no operation-related death.
• Good pathological responses were observed in 12 cases with lesions in the lymph nodes (complete response, n=4; partial response, n=8) and 11 pts with primary stomach lesions (complete response, n=2; partial response, n=9).

Today in GI Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09

Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study
British Journal of Cancer, 11/18/09

See All of GI Oncology